Year: 2025
Type: article
Abstract: : Dual Antiplatelet Therapy (DAPT) is a cornerstone in managing thrombotic cardiovascular conditions, particularly in patients undergoing percutaneous coronary intervention (PCI), those with acute coronary syndrome (ACS), and individuals at risk of cerebrovascular and peripheral arterial events. This review explores the mechanisms of various antiplatelet agents, their clinical indications, and the optimal duration of DAPT across different patient populations. While DAPT effectively reduces ischemic complications, prolonged therapy is associated with an increased risk of bleeding, necessitating a tailored approach based on individual risk assessments. Recent advancements, including novel antiplatelet agents and evolving guidelines, emphasize balancing ischemic protection with bleeding risk. This review provides an in-depth analysis of the latest clinical evidence, emerging therapies, and guideline recommendations for optimizing DAPT in various cardiovascular conditions
Authors: Tribhav Rathod, Gajanand Chame, Yogesh Sawant
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: American Heart Association
OpenAlex ID: W4409391043